Skip to main content
NCBI home page
Frontiers in Pharmacology logoLink to Frontiers in Pharmacology
. 2026 May 20;17:1803145. doi: 10.3389/fphar.2026.1803145

Polyphyllin B induces ferroptosis in triple-negative breast cancer by inactivating NRF2

Ping Deng 1,†, Shouhai Zhu 2,†, Yuxuan Wu 3, Zhiju Fang 1, Aini Zhang 1, Dongyi Zhang 1, Xiaoqu Hu 1,*, Xiang Zhou 1,*
PMCID: PMC13229704  PMID: 42244877

Abstract

Background

Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer (BC) and lacks effective treatment options. Polyphyllin B (PB), a saponin extracted from Paris formosana Hayata, has shown potential in cancer therapy. However, its anti-TNBC effects and mechanisms are not well studied. This study investigated the effects and underlying mechanisms of PB in TNBC.

Methods

CCK8 assay, Wound healing assay, Transwell migration experiments, and clonogenic assay were performed to assess the effects of PB in three TNBC cells lines. Iron level, lipid ROS, and MDA levels were assessed as ferroptosis markers. Mechanistic studies were conducted using molecular docking, Western blot, immunofluorescence, RT-qPCR, Nrf2 overexpression assays and establishment of a TNBC mouse model.

Results

PB treatment resulted in significant cell death and inhibited the migration of TNBC cells. Accumulation of iron and MDA suggested that PB induces ferroptosis. In vitro and in vivo, PB downregulated the expression of nuclear factor E2-related factor 2 (NRF2) and sequestosome-1 (P62) and upregulated the expression of Kelch-like ECH-associated protein 1 (KEAP1). Furthermore, it modulated the expression of key ferroptosis regulators, including acyl-CoA synthetase long-chain family member 4 (ACSL4) and glutathione peroxidase 4 (GPX4). In a TNBC mouse model, PB suppressed tumor growth and increased malondialdehyde accumulation.

Conclusion

PB inhibits cell proliferation and migration and induces ferroptosis in TNBC through the inactivation of NRF2. PB is a promising candidate for TNBC treatment that warrants further investigation.

Keywords: breast cancer, ferroptosis, Nrf2, polyphyllin B, triple negative breast cancer

Introduction

BC is one of the most prevalent malignancies among women worldwide (Li Y. et al., 2022). According to global statistics, there were about 2.3 million new breast cancer cases and 0.67 million deaths in 2022, which accounted for about 6.9% of all cancer deaths (Bray et al., 2024; Fu et al., 2025), making breast cancer the second leading cause of cancer-related deaths (Sung et al., 2021). TNBC accounts for approximately 15% of all BC cases (Mehraj et al., 2022). TNBC has high mortality and recurrence rates due to its high tumor heterogeneity (Li Y. et al., 2022; Yang et al., 2023), specific mutations, and abnormal activation of signaling pathways (Derakhshan and Reis-Filho, 2022), all of which complicate the identification of effective therapeutic targets (Li Y. et al., 2022). Currently, the primary treatments for TNBC are surgery, radiotherapy, and chemotherapy. However, these treatments cannot cure all patients, necessitating the development of new therapies.

Ferroptosis is a newly discovered cell death pattern distinct from autophagy and apoptosis (Stockwell et al., 2017) and is characterized by lipid peroxidation and iron accumulation. Morphologically, it is characterized by reduced mitochondrial volume, increased bilayer membrane density, and loss of mitochondrial cristae (Li J. et al., 2020; Dixon et al., 2012). Biochemically, ferroptosis is regulated by various factors, including GPX4 and ACSL4. GPX4 inhibits lipid peroxidation, whereas ACSL4 activates the iron-containing enzyme lipoxygenase during ferroptosis (Yan et al., 2021). Recent studies have indicated that TNBC exhibits heterogeneous phenotypes in terms of ferroptosis-related metabolites and metabolic pathways (Yang et al., 2023; Wang Z. et al., 2023). Abundant transferrin receptors on the TNBC cell surface indicate a high capacity for iron uptake. High iron levels can reprogram cellular metabolism and satisfy the rapid growth and proliferation requirements of cancer cells. GPX4 and GSH are necessary for TNBC cells to escape from oxidative stress. Based on this heterogeneity, targeting ferroptosis can be used to reverse chemotherapeutic resistance in TNBC treatments; finding new ferroptosis inducers and targeting the regulator of ferroptosis are potential therapeutic strategies in TNBC (Li et al., 2023a; Szulc and Woźniak, 2025; Jiang et al., 2021).

NRF2 plays an important role in ferroptosis by inhibiting iron accumulation and limiting ROS production (Mou et al., 2019). Normally, NRF2 is regulated by the ubiquitination and proteasomal degradation of KEAP1 (Adinolfi et al., 2023). There are conflicting perspectives regarding NRF2’s role in tumor therapy. Some research suggests activation of NRF2 is helpful for cancer treatment as it can prevent chemical carcinogen-mediated carcinogenesis. Others believe that inhibition of NRF2 is beneficial, as it can enhance chemotherapeutic efficacy in certain cancers, such as lung cancer. Recently, the effects of NRF2 have gained research interest, with the KEAP1/NRF2 signaling pathway shown to inhibit ferroptosis in several cancer types (Ren et al., 2011; Chowdhry et al., 2013; Lien et al., 2016).

PB, a saponin isolated from Paris formosana Hayata (Wu et al., 1990), has been previously demonstrated to exert anti-tumor effects in lung cancer (Li et al., 2023b), gastric cancer (Hu et al., 2023), and hepatocellular carcinoma (Lin et al., 2020). In this study, we demonstrated that PB is an effective natural product extract against TNBC. We further investigated its potential mechanism in TNBC, revealing that PB serves as a novel ferroptosis inducer by inhibiting NRF2 and GPX4. These results provide a theoretical basis for the future clinical application of PB in treating TNBC.

Materials and methods

Reagents and antibodies

PB (CAS: 50773-42-7, purity: >=98%) was purchased from ChemFaces (Wuhan, Hubei, China). Fer-1(CAS: 347174-05-4, purity: 99.71%) was purchased from MedChemExpress (MCE) (Shanghai, China).

Cell culture

HS-578T, MDA-MB-231, and BT-549 cells were obtained from the Cell Bank of the Shanghai Institute of Biochemistry and Cell Biology (Shanghai, China). HS-578T and MDA-MB-231 cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) (Gibco, Germany) containing 10% fetal bovine serum (FBS) (Thermo Fisher Scientific Inc, USA) in a humidified atmosphere with 5% CO2 at 37 °C. BT-549 cells were cultured in RPMI-1640 (Gibco, Germany) containing 10% FBS in a humidified atmosphere with 5% CO2 at 37 °C.

Cell viability assay

Approximately 5000 cells were seeded into 96-well plates and incubated overnight. Subsequently, the TNBC cells were treated with increasing concentrations of PB (0.625, 1.0, 1.25, 2, 2.5, 3.0, 5.0 μM) for 24 h or 48 h. Cell Counting Kit-8 (CCK8) (Dojindo, Japan) reagent (10 µL/well) was added to the plates and then incubated at 37 °C for 2 h. Absorbance was then measured at 450 nm. Cell viability was assessed using GraphPad Prism 9.0.

Wound healing assay

TNBC cells were seeded into 6-well plates. When the cells had grown to 80%–90% confluence, a sterile 10 μL pipette tip was used to scrape the cell monolayer and create linear scratch wound. Then, the wells were washed with PBS to remove detached cells from the plates. Cells were cultured in serum-free medium with or without PB (0.5 µM) for 48 h. Images were taken at 0 h, 24 h, and 48 h to track cell migration into the wound area using a microscope (Leica, Wetzlar, Germany).

Transwell migration experiments

Approximately 3 × 104 cells were suspended in 200 µL of serum-free medium and seeded into the upper chambers of the Transwell plates, treated with or without PB (0.5 µM). 500 μL of complete medium containing 20% FBS was added to the lower chambers of Transwell plates. After 48 h, the cells on the upper surface of the membrane were removed with sterile cotton swabs and washed with PBS. Then the membranes were stained with crystal violet and analyzed under a microscope (Leica, Wetzlar, Germany).

Colony assay

Approximately 1000 cells were seeded into 6-well plates and treated with PB (0.5 µM), either alone or in combination with Fer-1 (1 μM), for 6–14 days. After the treatment period, the cells were fixed with 4% paraformaldehyde, stained with crystal violet (Biosharp, China) for 20 min, and then air-dried.

Measurement of iron contents

The iron concentration in TNBC cells was measured using the Iron Colorimetric Assay Kit (ab83366, Abcam) according to the manufacturer’s protocol. Briefly, approximately 2 × 106 cells were rapidly homogenized in iron assay buffer on ice. After centrifugation, the supernatant was collected and mixed with assay buffer, then incubated for 30 min at room temperature. Next, 100 μL of iron probe was added, mixed and incubated at 37 °C for 60 min in the dark. Finally, the absorbance was measured at 593 nm using a microplate reader.

Western blot

Proteins from tumor tissues and cells were extracted using Radio-Immunoprecipitation Assay buffer (RIPA, Beyotime), separated on 10% or 12.5% sodium dodecyl sulfate-polyacrylamide gels, and transferred to polyvinylidene fluoride (PVDF) membranes (Millipore, United States). Membranes then were blocked with 5% skim milk at room temperature for 2 h. They were then incubated with primary antibodies overnight at 4 °C, then washed three times with Tris-buffered saline containing 0.5% Tween-20 (TBST), incubated with secondary antibodies for 1 h at room temperature the following day. The primary antibodies used in Western blot assays include anti-P62 (18420-1-AP, Proteintech), anti-KEAP1 (10503-2-AP, Proteintech), anti-NRF2(16396-1-AP, Proteintech), anti-ACSL4 (EPR8640, Abcam), anti-GPX4 (67763-1-Ig, Proteintech) and anti-GAPDH (10494-1-AP, Proteintech), the secondary antibodies include HRP-conjugated goat anti-mouse IgG (H + L) (SA00001-1, Proteintech) and HRP-conjugated goat anti-rabbit IgG (H + L) (SA00001-2, Proteintech). Immunoreactive bands were visualized using an enhanced chemiluminescence (ECL) detection system, and densitometric quantification was performed using ImageJ software.

Real-time quantitative PCR

RNA from TNBC cells was extracted with TRIzol and reverse-transcribed into cDNA. RT-qPCR was performed using Taq polymerase (TAKARA, Japan). GAPDH was used as the reference gene for normalization, and the relative expression levels of target genes were calculated using the ΔΔCq method. The primer sequences (5′→3′) for the target genes, bought from Sangon Biotech (Shanghai, China), are as follows: 5′-TGA​TTG​AGT​CCC​TCT​CCC​AGA​TGC-3′ (P62,F) and 5′-GCC​GCT​CCG​ATG​TCA​TAG​TTC​TTG-3′ (P62,R); 5′-CCTGGACAGTGTGGAGTGTTACG-3′(Keap1,F) and 5′-AGTTCTGCTGGTCAATCTGCTTCC-3′(Keap1,R); 5′-AGTCCAGAAGCCAAACTGACAGAAG-3′(NRF2,F) and 5′-GGAGAGGATGCTGCTGAAGGAATC-3′(NRF2, R); 5′-GGTCGGAGTCAACGGATTTG-3′(GAPDH,F) and 5′-ATGAGCCCCAGCCTTCTCCAT-3′(GAPDH,R).

Measurement of lipid ROS

To investigate ROS generation, approximately 5 × 104 cells were seeded in 6-well plates and treated with PB (0.5 μM), either alone or in combination with Fer-1 (1 μM) for 48 h. Subsequently, these cells were incubated with 10 µM DCFH-DA (S0033, Beyotime) for 20 min at 37 °C in a light-free environment. Finally, images were captured using a fluorescence microscope.

Molecular docking and bioinformatic analysis

Molecular docking was performed using Auto Dock Vina software. The crystal structure of GPX4 and NRF2 were retrieved from the Research Collaboratory for Structural Bioinformatics Protein Data Bank (PDB, http://www.rcsb.org/pdb/). The PB structure was obtained from the PubChem Compound Database (https://pubchem.ncbi.nlm.nih.gov/). The best-fit complexes were visualized and analyzed using PyMOL 2.4.0.

The mRNA expression levels of GPX4 and NRF2 in tumors and adjacent normal tissues across a pan-cancer dataset were analyzed via the TIMER database (TIMER1.0, https://compbio.cn/timer1/), Kaplan-Meier survival analysis of NRF2 expression in BC was conducted using data from the TCGA database.

Cell transfection

MDA-MB-231 cells were transfected with an NFE2L2 (NRF2) overexpression plasmid (Gene Chem, Shanghai) using Lipofectamine™ 2000 (Invitrogen, United States) transiently, according to the manufacturer’s instructions. After 24 h, the efficiency of overexpression was confirmed via western blotting and immunofluorescence analysis.

Immunofluorescence staining

TNBC cells were seeded on glass slides in 24-well plates and treated with PB (0.5 μM), either alone or in combination with Fer-1 (1 μM) for 48 h. Subsequently, the cells were fixed with 4% paraformaldehyde and permeabilized with 0.1% Triton X-100 (Solarbio, China), followed by blocking with goat serum (BOSTER, China). Next, the cells were incubated with primary antibodies overnight and then incubated with secondary antibodies for 1 h. DAPI was used to visualize the nuclei. After sealing with an anti-fluorescence quencher, the slides were imaged by fluorescence microscope (Leica, Germany).

Animal experiment protocol

Four-week-old female BALB/c-nu nude mice were obtained from the Laboratory Animal Center of Wenzhou Medical University (Wenzhou, China), and the study was approved by the ethics committee of Wenzhou Medical University (WYYY-AEC-YS-2024-0534). A total of 100 μL PBS containing 2 × 106 MDA-MB-231 cells was injected subcutaneously into mice. When the tumor volume reached approximately 50 mm3, the mice were randomly divided into three experimental groups (five mice per group) with similar mean body weights and tumor volumes: a PBS control group, a 2 mg/kg PB treatment group, and a 2 mg/kg PB + 1 mg/kg Fer-1 combination treatment group, followed by intraperitoneal injection of the corresponding treatments every other day for 2 weeks. The tumor size and body weight of the mice were recorded every other day throughout the study period. Finally, the mice were euthanized by cervical dislocation, and the tumors were collected for histological and western blot analyses.

Measurement of malondialdehyde (MDA) levels

Lipid peroxidation in tumor tissues was assessed by measuring the concentration of MDA using an MDA Assay Kit (S0131, Beyotime) in accordance with the manufacturer’s instructions.

Hematoxylin and eosin (HE) staining and immunohistochemistry (IHC)

All experiments were repeated independently at least three times. All data were expressed as the mean ± standard deviation (SD). Statistical comparisons between two or more groups were performed using Kruskal–Wallis analysis of variance and multifactorial ANOVA, while other analyses utilized the t-test. A P-value of <0.05 was considered statistically significant. GraphPad Prism 8.0 (San Diego, CA, USA) was used for all statistical analyses.

Statistical analysis

All experiments were repeated independently at least three times. All data were expressed as the mean ± standard deviation (SD). Statistical comparisons between two or more groups were performed using Kruskal–Wallis analysis of variance and multifactorial ANOVA, while other analyses utilized the t-test. A P-value of <0.05 was considered statistically significant. GraphPad Prism 8.0 (San Diego, CA, USA) was used for all statistical analyses.

Results

PB inhibited the proliferation of TNBC cells in vitro

Several experiments were conducted to assess the effects of PB (Figure 1A), on TNBC cells. Phase-contrast microscopy revealed noticeable morphological changes in cells, such as cell rounding and decreased cell numbers (Figure 1B), which suggested inhibition of cell viability by PB. CCK8 assays revealed that PB significantly inhibited cell proliferation in a dose-dependent manner with the 48-h treatment being more effective. The 48-h IC50 values for PB were determined to be 1.183 μM in MDA-MB-231 cells, 1.009 μM in HS-578T cells, and 0.5371 μM in BT-549 cells (Figures 1C–E). Wound healing and Transwell migration assays showed that PB inhibited the migration capacity of TNBC cells (Figures 1F–H), and colony assays showed it also suppressed colony formation in these cells (Figures 1I,J). Collectively, these findings demonstrated that PB effectively inhibited the growth and survival of TNBC cells in vitro.

FIGURE 1.

Structural diagram of Polyphyllin B with labeled atoms shown in panel A. Panel B displays microscopy images comparing cell morphology of MDA-MB-231, HS-578T, and BT-549 breast cancer cell lines between control and Polyphyllin B-treated groups. Panels C, D, and E present line graphs showing decreased cell viability at multiple concentrations and time points for each cell line. Panel F contains wound healing assay images at zero, twenty-four, and forty-eight hours, with reduced migration in Polyphyllin B-treated groups visually marked. Panel G features grouped bar graphs quantifying area recovery percentage, showing significant migration inhibition with Polyphyllin B in all cell lines. Panel H includes stained images from transwell assays, demonstrating reduced invasion with Polyphyllin B treatment. In panel I, circular colony formation assays reveal fewer and smaller colonies after Polyphyllin B treatment. Panel J offers bar graphs with quantified relative colony area for each cell line, showing significant reduction in Polyphyllin B-treated groups.

Open in a new tab

PB inhibits the proliferation of TNBC cells in vitro. (A) Chemical structure of PB. (B) Phase-contrast microscopic images of TNBC cells with or without PB treatment (magnification, 10×). (C–E) The effects of PB on the proliferation of TNBC cells were determined through CCK8 assays. (F,G) Wound healing assays of TNBC cells with or without PB treatment, followed by quantitative analysis. (H) Transwell assays of TNBC cells with or without PB treatment. Bar = 200 μm. (I,J) Colony assays of TNBC cells with or without PB treatment, followed by quantitative analysis. *P < 0.05, **P < 0.01.

PB induced ferroptosis in vitro

TNBC is particularly susceptible to ferroptosis and ferroptosis has been demonstrated to be a potential therapeutic target for TNBC (Verma et al., 2020). Ferroptosis is a type of cell death characterized by iron dependence and lipid peroxidation. To determine whether PB induces ferroptosis, TNBC cells were treated with PB alone or in combination with the ferroptosis inhibitor Fer-1 for 48 h. CCK8 assays showed that the anti-proliferative effects of PB were rescued by Fer-1 (Figure 2A). Additionally, PB induced iron accumulation and this accumulation was further reduced by Fer-1 (Figure 2B). In colony assays, Fer-1 reduced the PB-mediated inhibition of colony formation ability (Figures 2C,D). Taken together, these results demonstrate that PB treatment triggers ferroptosis in TNBC cells.

FIGURE 2.

Panel of scientific data from cell viability, colony formation, western blot, immunofluorescence, and statistical bar graphs comparing control, PB, PB+Fer-1, and Fer-1 conditions across MDA-MB-231, HS-578T, and BT-549 cell lines; results indicate differences in viability, Fe2+ levels, protein expression (ACSL4, GPX4), and fluorescent staining, suggesting treatment effects analyzed statistically.

Open in a new tab

PB induces ferroptosis in vitro. (A) Viability of TNBC cells treated with PB or in combination with Fer-1 for 48 h, assessed via CCK8 assay. (B) Measurement of iron levels to evaluate the iron accumulation in TNBC cells. (C,D) Proliferative ability of TNBC cells treated with PB or in combination with Fer-1 for 48 h, assessed via Colony assays. (E) TIMER database online analysis results of GPX4. (F–I) Protein expression of ACSL4 and GPX4 in TNBC cells. (J) ROS levels in TNBC cells. (K,L) Immunofluorescence analysis of ACSL4 and GPX4 in TNBC cells. *P < 0.05, **P < 0.01, ***P < 0.001.

Ferroptosis is regulated by GPX4 and ACSL4 (Glibetic and Weichhaus, 2025). GPX4 is a central inhibitor of ferroptosis, collaborates with glutathione to covert lipid peroxidation and inhibit ROS accumulation indirectly (Bersuker et al., 2019). Our analysis of the TIMER database revealed a difference in GPX4 mRNA expression between breast tumors and adjacent normal tissues (Figure 2E). When GPX4 is in inactivated or absent, ACSL4 become indispensable for lipid peroxidation in ferroptosis (He et al., 2022). Therefore, we examined the protein expression and fluorescence intensities of GPX4 and ACSL4 in TNBC cells. The results showed that PB effectively decreased GPX4 protein expression and elevated ACSL4 protein expression in TNBC cells (Figures 2F–I). With substrates provided by ACSL4 and loss of the quenching function of GPX4, ROS production increased through the iron-mediated Fenton reaction, as expected (Figure 2J). Changes in the fluorescence intensities of GPX4 and ACSL4 correlated with changes in their protein expression levels (Figures 2K,L). These effects were partly reversed by Fer-1. In conclusion, our findings indicate that the anticancer effect of PB is partly attributable to ferroptosis in TNBC cells, a process mediated by GPX4 and ACSL4.

PB suppressed TNBC cells by inactivating NRF2

Studies have demonstrated that total saponins extracted from Rhizoma Paridis can alleviate oxidative stress injury by upregulating the NRF2 pathway, but it remains unclear which specific saponins mediate this effect and what the underlying mechanism is (Zhao et al., 2020). The antioxidant, iron, and intermediate metabolic statuses of cells are inseparable from the regulation by NRF2, which has been shown to be a critical regulator of ferroptosis and GPX4 (Dodson et al., 2019).

Through TIMER database analysis, we focused on the differences in NRF2 mRNA expression between tumors and adjacent normal tissues (Figure 3A), so we further explored the effects of NRF2 on BC survival. Using TCGA clinical data with a survival period of more than 5 years, we found that low NRF2 expression is associated with the long-term survival of patients (Figure 3B). Molecular docking assays revealed the binding sites each for PB with NRF2 and with GPX4, and the binding energies were measured as −11.8 kcal/mol and −8.7 kcal/mol, respectively (Figures 3C,D). Based on the higher binding energies, we indicated NRF2 as the primary binding partner of PB. Next, we examined the gene and protein expression of NRF2 in TNBC cells, the results showed that PB dramatically reduced both the protein and gene expression of NRF2 (Figures 3E–G), while Fer-1 only reversed the decrease in NRF2 protein expression. These findings suggest that PB acts on TNBC cells partly relay on NRF2.

FIGURE 3.

Panel A shows a boxplot comparing NFE2L2 gene expression across different cancer types, with high and low expression marked in red and blue. Panel B presents a Kaplan-Meier survival curve showing reduced overall survival in patients with high NFE2L2 expression. Panels C and D display molecular docking illustrations, highlighting interactions between a ligand and specific protein residues in different protein models with surface and ribbon views, including close-ups of binding sites. Panels E and J show representative Western blot images for NRF2, P62, KEAP1, and GAPDH across three breast cancer cell lines under different treatment conditions. Panels F, G, H, I, and K provide corresponding bar graphs quantifying protein or gene expression levels in the experimental groups, with error bars indicating variability.

Open in a new tab

PB induces ferroptosis by inactivating NRF2. (A) TIMER database online analysis results of NRF2. (B) Kaplan-Meier survival curve of NRF2 in BC based on TCGA database. (C,D) Molecular docking results between PB and NRF2 with GPX4. (E–G) The gene and protein expression of NRF2 in TNBC cells, followed by quantitative analysis. (H,I) The gene expression of P62 and KEAP1. (J,K) The protein expression of P62 and KEAP1, followed by quantitative analysis. *P < 0.05, **P < 0.01.

As NRF2 expression is commonly regulated by P62 and KEAP1 (Li T. et al., 2020; Liu et al., 2023), we further examined the protein and gene expression of P62 and KEAP1.These results showed that PB decreased both the gene and protein expression of P62, while it increased those of KEAP1. In contrast, Fer-1 reversed the protein expression without affecting the gene expression of either P62 or KEAP1 (Figures 3H–K). Therefore, we further conclude that PB-resulted ferroptosis via the NRF2 pathway is modulated by P62 and KEAP1.

NRF2 negatively regulated ferroptosis induced by PB

We established NRF2-overexpression MDA-MB-231 cells to investigate the effects of NRF2 on cell proliferation and ROS production in TNBC (Figures 4A–C). The CCK8 results revealed that overexpression of NRF2 partially counteracted the inhibitory effect of PB on cell proliferation (Figure 4D). With the treatment of PB, GPX4 protein expression was not decreased but increased, while ACSL4 protein expression decreased in NRF2-overexpression cells (Figures 4E–G). These protein expression changes were further verified by immunofluorescence staining (Figure 4J). Furthermore, overexpression of NRF2 partly suppressed the production of ROS induced by PB (Figure 4H). However, in the NRF2-overexpressing cells, P62 and KEAP1 protein expression were not significantly affected by PB, compared with the protein expression changes in cells transfected with an empty vector (Figure 4I). These results suggested that PB induces ferroptosis through NRF2, with GPX4 and ACSL4 acting as downstream effectors, while P62 and KEAP1 likely act as upstream effectors.

FIGURE 4.

Western blots, bar graphs, immunofluorescence images, and cell viability assays display comparative analyses between NC and OE groups, investigating NRF2, ACSL4, GPX4, and related proteins under multiple treatments, with quantitative results presented alongside representative microscopy images and fluorescence intensities.

Open in a new tab

NRF2 inhibits PB-induced ferroptosis. (A–C) Relative protein expression was measured by western blotting and immunofluorescence in NRF2-overexpressing cells, followed by quantitative analysis. *P < 0.05, **P < 0.01, ***P < 0.001. (D) CCK8 assays in NRF2-overexpressing cells. (E–G) Protein expression of ACSL4, and GPX4 in NRF2-overexpressing cells, followed by quantitative analysis. (H) ROS levels in NRF2-overexpressing cells. (I) Protein expression of P62, and KEAP1 in NRF2-overexpressing cells. (J) Immunofluorescence analysis of ACSL4 and GPX4 in NRF2-overexpressing cells.

PB suppressed tumor growth and induced ferroptosis in vivo

To evaluate the antitumor activity of PB in vivo, we established a mouse xenograft tumor model using MDA-MB-231 cells. Tumor imaging and measurements of tumor weight and volume revealed that xenograft tumors in PB-treated mice grew more slowly than those in PBS-treated mice (Figures 5A–C). Throughout the experiment, there were no abnormalities in eating or behavioral activities were observed in any of the groups (PBS, 2 mg/kg PB, and 2 mg/kg PB + 1 mg/kg Fer-1). Although body weight increased in both the PB-treated and combination-treated groups, the rate of body weight gain was slower than that in the control group (Figure 5D).

FIGURE 5.

Panel A shows excised tumor samples from three groups labeled control, PB, and PB plus Fer-1, with visible size differences. Panel B presents a line graph of tumor volume over time for each group, indicating the PB group has reduced tumor volume compared to control, with PB plus Fer-1 reversing this effect. Panel C is a bar graph showing mean tumor weight, with the PB group lower than control and the PB plus Fer-1 group intermediate. Panel D shows body weight over time, with no substantial differences between groups. Panel E displays a western blot image for ACSL4, GPX4, and GAPDH, corresponding to protein expression levels in each group. Panel F quantifies protein expression via a bar graph for ACSL4 and GPX4, showing changes between groups. Panel G features immunohistochemistry and hematoxylin-eosin staining images for Ki67, GPX4, ACSL4, and HE in all groups. Panels H, I, J, and K show bar graphs quantifying mean optical density or percent positivity for markers Ki67, GPX4, ACSL4, and MDA levels, showing significant differences between groups with statistical annotations.

Open in a new tab

PB induces ferroptosis in vivo. (A) Photographs of tumors. (B) Tumor volumes and (C) Tumor weights. The data are presented as means ± SDs, with n = 5. (D) Mice weight. (E,F) The protein expression of ACSL4 and GPX4 in subcutaneous xenografts, followed by quantitative analysis. (G–J) Immunohistochemical staining of tumor sections for the cell proliferation marker Ki-67, ferroptosis markers ACSL4 and GPX4, and Hematoxylin and Eosin (H&E), followed by quantitative analysis. Bar = 100 μm (K) The MDA level in subcutaneous xenografts. *P < 0.05, **P < 0.01, ***P < 0.001.

Ki67 staining was consistently weaker in the PB-treated group than in the control group (Figure 5G). Fer-1 reversed this reduction. Similarly, PB treatment significantly decreased GPX4 expression but increased ACSL4 expression (Figures 5E–J). The level of MDA was also reduced in the PB-treated group (Figure 5K). These results demonstrate that PB inhibited the proliferation of MDA-MB-231 cells and induced ferroptosis in vivo. Western blotting and immunohistochemical results revealed that PB treatment reduced P62 and NRF2 levels and elevated KEAP1 levels (Figures 6A–F), which suggests that PB exerts its antitumor effect by inhibiting NRF2, a mechanism that may be regulated by P62 and KEAP1. The levels of ALT and CR in peripheral blood suggested that PB did not cause significant host toxicity during the treatment period at this effective dose (Figures 6G,H).

FIGURE 6.

Scientific figure with multiple panels. Panel A shows a western blot of P62, KEAP1, NRF2, and GAPDH protein levels across control, PB, and PB plus Fer-1 groups. Panel B displays a bar graph comparing relative protein expression of P62, KEAP1, and NRF2 with statistical significance denoted. Panel C contains immunohistochemistry images for P62, KEAP1, and NRF2 across control, PB, and PB plus Fer-1 groups. Panels D, E, and F show bar graphs of mean optical density values for P62, KEAP1, and NRF2, respectively. Panels G and H present bar graphs of ALT and CR levels among the three groups.

Open in a new tab

PB induces ferroptosis through NRF2 in vivo. (A,B) The protein expression of P62, KEAP1, and NRF2 in subcutaneous xenografts, followed by quantitative analysis. (C) Immunohistochemical staining of tumor sections for P62, KEAP1, and NRF2, followed by quantitative analysis. Bar = 100 μm *P < 0.05, **P < 0.01 (D–F). (G,H) The level of ALT and CR in peripheral blood of mice model.

Discussion

TNBC has the worst prognosis among all BC subtypes. Despite the development of emerging immunotherapies in recent years, their efficacy is still limited to a subset of patients and exists resistance (Zhu et al., 2021). Therefore, the identification of novel molecular targets and therapeutic agents is crucial. Rhizoma Paridis is a traditional Chinese medicine known for its heat-clearing and detoxification properties (Li J. K. et al., 2022; Zhou et al., 2023). Previous studies have demonstrated the anticancer properties of steroidal saponin isolated from Rhizoma Paridis (Wang Y. et al., 2023; Yang et al., 2024). For example, polyphyllin I causes cell cycle arrest, ultimately leading to cancer cell death (Yu et al., 2018); Polyphyllin II triggers autophagy in colorectal cancer cells (Li J. K. et al., 2022); and Polyphyllin G induces both apoptosis and autophagy in human nasopharyngeal cancer cells (C et al., 2016). However, the specific mechanism of PB in TNBC remains unclear.

Here, we observed that PB inhibited the proliferation and migration capacities of TNBC cells in vitro, induced cell death, and suppressed tumor growth in vivo. All these effects were associated with ferroptosis. Mechanistically, we demonstrated that PB induced ferroptosis via NRF2 downregulation, leading to reduced GPX4 expression and the loss of GPX4 quenching function to lipid peroxidation. Concurrently, increased ACSL4 expression and iron accumulation elevated ROS and MDA production, ultimately triggering ferroptosis in TNBC (Figure 7).

FIGURE 7.

Diagram compares regular Nrf2 versus overexpressed Nrf2 within a cell, illustrating ferroptosis pathways. Key molecules P62, Nrf2, Keap1, Fe2+, ROS, MDA, GPX4, and ACSL4 are shown with arrows denoting increased or reduced expression and relationships. Overexpression of Nrf2 promotes antioxidant response and inhibits ferroptosis, while regular Nrf2 leads to increased ferroptosis through elevated ROS and MDA and reduced GPX4. ARE binding is indicated, and mechanisms of promotion and inhibition are marked by arrows. Legend at the bottom defines arrow meanings.

Open in a new tab

Mechanism.

Ferroptosis is a new form of programmed cell death characterized by iron-dependent lipid peroxidation (Li J. et al., 2020). It can enhance immune responses and help overcome immunotherapy resistance to cancer (Liu et al., 2026), as well as cause cancer cells death by resulting in accumulation of lipid peroxides and iron, it can also reshape the immune microenvironment and alter the susceptibility of tumor cells to ferroptosis (Chen et al., 2026; Jia et al., 2026; Xu et al., 2022). Ferroptosis has demonstrated anticancer properties in various cancers, particularly in TNBC. TNBC has high iron levels and low antioxidant capacity, which make it susceptible to ferroptosis (Tan et al., 2025). Interestingly, in this study, PB increased ROS production and iron accumulation in TNBC cells, and elevated MDA levels in a TNBC mouse model. Importantly, all these effects were reversed by Fer-1, indicating that PB can induce ferroptosis and cause cell death in TNBC.

GPX4 and ACSL4 are key marker proteins of ferroptosis. Previous studies have shown that ACSL4 and GPX4 double KO cells exhibit stronger proliferative capacity than normal cells, implicating an important functional interplay between GPX4 and ACSL4 (Doll et al., 2017). As a central repressor of ferroptosis, GPX4 influences lipid and amino acid metabolism, as well as processes such as cell aging, oncogenesis, and cell death. GPX4 can convert the toxic lipid peroxidation and then mitigate cellular damage from ferroptosis. In the condition of GPX4 inhibition or absence, ACSL4 catalyzes the synthesis of long-chain polyunsaturated-CoAs, triggering phospholipid peroxidation and supplying substrates for ferroptosis (Qiu et al., 2024; Chen et al., 2021a; Zefrei et al., 2024). In our study, PB treatment downregulated both the gene and protein expression of GPX4 in vitro and in vivo, without GPX4 activity and with enhanced ACSL4 catalytic function, lipid peroxidation and ROS production increased accordingly, leading to ferroptosis in TNBC cells. Therefore, we propose that PB functions as an inhibitor of GPX4 in ferroptosis and its effect may not be limited to TNBC based on previous research (Hu et al., 2023).

NRF2 is a member of the cap ‘n’ collar family of basic leucine zipper transcription factors (Chen et al., 2021b), Previous studies have proofed NRF2 as a central regulator of ferroptosis and oxidative stress responses (Sun et al., 2016; Tunc et al., 2025), GPX4 transcription need NRF2 migrates to the nucleus and its initiation (Cheng et al., 2021). NRF2 role in breast cancer presents two opposing perspectives. Some researchers propose that NRF2 protects breast cancer cells by resisting oxidative stress, while others argue that it promotes cell death by enhancing it (Wang Z. et al., 2023; Luo et al., 2024). In PB-induced ferroptosis, we observed a significant decrease in NRF2 expression. By establishing an NRF2 overexpression model, we found that NRF2 overexpression inhibited PB-induced ferroptosis, decreased ACSL4 expression, and increased GPX4 expression, resulting in reduced ROS accumulation. Integrating these findings with existing studies, we conclude that NRF2 acts as a ferroptosis inhibitor that counteracts the anticancer activity of PB in TNBC.

The activity of NRF2 is primarily controlled by its endogenous inhibitor, KEAP1 (Gelerstein-Claro et al., 2025). In our study, KEAP1 expression increased and P62 expression decreased as expected following PB treatment. These changes were consistent with NRF2 decreased expression but were not significantly affected by NRF2 overexpression. So, we propose that NRF2 functions as an inhibitor of ferroptosis in PB treatment, with P62 and KEAP1 maybe the upstream regulatory factors of NRF2. However, the specific mechanisms by which P62 and KEAP1 interact to regulate NRF2 degradation following PB exposure remain unclear and warrant further investigation, representing a limitation of this study.

This study uncovers a novel anti-tumor mechanism of PB in TNBC. PB downregulates NRF2 activity, leading to reduced expression of GPX4 and increased expression of ACSl4, with iron accumulation. These changes collectively promote lipid peroxidation, culminating in ferroptosis and thereby exerting anticancer effects. We validated that PB induces TNBC cell death in vitro and suppresses tumor growth in vivo. However, several questions remain. The functional interplay between the observed changes in P62 and KEAP1 expression, as well as the specifics of NRF2 nuclear translocation and GPX4 activation, require further experimental validation. As cell death is a complex process influenced by many factors, for example, recent studies have indicated the special role of MDM2 (Wang et al., 2025; Todoric et al., 2017) and FOXC2 (Zhao et al., 2026) in TNBC. Whether any other signaling pathway or regulator contributes to PB-induced TNBC cell death also needs deep exploration. What’s more, while the overall trends were consistent, differences observed among the three TNBC cell lines merit future investigation to explain their variable responses.

Conclusion

In conclusion, our findings provide compelling evidence that PB suppresses TNBC progression by inducing ferroptosis through NRF2 inhibition, a process mediated through the regulation of its downstream effectors, GPX4 and ACSL4. The high therapeutic efficacy and low toxicity observed in mouse models suggest that PB is a promising candidate for TNBC therapy. Further investigation of the therapeutic effects of PB in clinical trials is warranted.

Funding Statement

The author(s) declared that financial support was received for this work and/or its publication. This work was supported by the Zhejiang Provincial Medical and Health Science and Technology Plan Project (No. 2024KY1254) and the Zhejiang Provincial Natural Science Foundation of China (No. LQ22H160022).

Edited by: Yuanliang Yan, Central South University, China

Reviewed by: Sayantap Datta, Johns Hopkins University, United States

Peng Zhao, Guizhou Medical University, China

Abbreviations: T, Alanine aminotransferase; BC, Breast cancer; CR, Creatinine; DMEM, Dulbecco’s modified Eagle medium; FBS, Fetal bovine serum; Fer-1, Ferrostatin-1; HCC, Hepatocellular Carcinoma; HE, Hematoxylin-eosin; MDA, Malondialdehyde; NSCLC, Non-small Cell Lung Cancer; PB, Polyphyllin B; ROS, Reactive Oxygen Species; TNBC, Triple negative breast cancer.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The animal study was approved by the Laboratory Animal Center of Wenzhou Medical University protocol code: WYYY-AEC-YS-2024-0534. The study was conducted in accordance with the local legislation and institutional requirements.

Author contributions

PD: Conceptualization, Investigation, Methodology, Software, Validation, Writing – original draft, Writing – review and editing. SZ: Conceptualization, Methodology, Writing – review and editing. YW: Formal Analysis, Investigation, Software, Writing – original draft. ZF: Software, Writing – original draft. AZ: Formal Analysis, Writing – original draft. DZ: Software, Writing – original draft. XH: Data curation, Project administration, Resources, Supervision, Validation, Writing – review and editing. XZ: Data curation, Project administration, Resources, Supervision, Validation, Writing – review and editing.

Conflict of interest

The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declared that generative AI was not used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

  1. Adinolfi S., Patinen T., Jawahar Deen A., Pitkänen S., Härkönen J., Kansanen E., et al. (2023). The KEAP1-NRF2 pathway: targets for therapy and role in cancer. Redox Biol. 63, 102726. 10.1016/j.redox.2023.102726 [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bersuker K., Hendricks J. M., Li Z., Magtanong L., Ford B., Tang P. H., et al. (2019). The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature 575, 688–692. 10.1038/s41586-019-1705-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bray F., Laversanne M., Sung H., Ferlay J., Siegel R. L., Soerjomataram I., et al. (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229–263. 10.3322/caac.21834 [DOI] [PubMed] [Google Scholar]
  4. Chen J. C., Hsieh M. J., Chen C. J., Lin J. T., Lo Y. S., Chuang Y. C., et al. (2016). Polyphyllin G induce apoptosis and autophagy in human nasopharyngeal cancer cells by modulation of AKT and mitogen-activated protein kinase pathways in vitro and in vivo . Oncotarget 7, 70276–70289. 10.18632/oncotarget.11839 [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Chen X., Kang R., Kroemer G., Tang D. (2021a). Broadening Horizons: the role of ferroptosis in cancer. Nat. Rev. Clin. Oncol. 18, 280–296. 10.1038/s41571-020-00462-0 [DOI] [PubMed] [Google Scholar]
  6. Chen X., Li J., Kang R., Klionsky D. J., Tang D. (2021b). Ferroptosis: machinery and regulation. Autophagy 17, 2054–2081. 10.1080/15548627.2020.1810918 [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Chen S., Chen Y., Xu Y., Song B. (2026). Harnessing tumor cell death mechanisms to reshape the immune microenvironment: a novel approach for head and neck cancer therapy. Int. Immunopharmacol. 171, 116132. 10.1016/j.intimp.2025.116132 [DOI] [PubMed] [Google Scholar]
  8. Cheng K., Huang Y., Wang C. (2021). 1,25(OH)(2)D(3) inhibited ferroptosis in zebrafish liver cells (ZFL) by regulating Keap1-Nrf2-GPx4 and NF-κB-hepcidin axis. Int. J. Mol. Sci. 22, 11334. 10.3390/ijms222111334 [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Chowdhry S., Zhang Y., McMahon M., Sutherland C., Cuadrado A., Hayes J. D. (2013). Nrf2 is controlled by two distinct β-TrCP recognition motifs in its Neh6 domain, one of which can be modulated by GSK-3 activity. Oncogene 32, 3765–3781. 10.1038/onc.2012.388 [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Derakhshan F., Reis-Filho J. S. (2022). Pathogenesis of triple-negative breast cancer. Annu. Rev. Pathol. 17, 181–204. 10.1146/annurev-pathol-042420-093238 [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Dixon S. J., Lemberg K. M., Lamprecht M. R., Skouta R., Zaitsev E. M., Gleason C. E., et al. (2012). Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 149, 1060–1072. 10.1016/j.cell.2012.03.042 [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Dodson M., Castro-Portuguez R., Zhang D. D. (2019). NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis. Redox Biol. 23, 101107. 10.1016/j.redox.2019.101107 [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Doll S., Proneth B., Tyurina Y. Y., Panzilius E., Kobayashi S., Ingold I., et al. (2017). ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat. Chem. Biol. 13, 91–98. 10.1038/nchembio.2239 [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Fu M., Peng Z., Wu M., Lv D., Li Y., Lyu S. (2025). Current and future burden of breast cancer in Asia: a GLOBOCAN data analysis for 2022 and 2050. Breast 79, 103835. 10.1016/j.breast.2024.103835 [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Gelerstein-Claro S., Méndez-Valdés G., Rodrigo R. (2025). Effects of the pharmacological modulation of NRF2 in cancer progression. Med. Kaunas. 61, 2224. 10.3390/medicina61122224 [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Glibetic N., Weichhaus M. (2025). Metabolic regulation of ferroptosis in breast cancer. Int. J. Mol. Sci. 26, 9686. 10.3390/ijms26199686 [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. He S., Li R., Peng Y., Wang Z., Huang J., Meng H., et al. (2022). ACSL4 contributes to ferroptosis-mediated rhabdomyolysis in exertional heat stroke. J. Cachexia Sarcopenia Muscle 13, 1717–1730. 10.1002/jcsm.12953 [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Hu C., Zu D., Xu J., Xu H., Yuan L., Chen J., et al. (2023). Polyphyllin B suppresses gastric tumor growth by modulating iron metabolism and inducing ferroptosis. Int. J. Biol. Sci. 19, 1063–1079. 10.7150/ijbs.80324 [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Jia X., Shi Y., Su J., Zhou Y., Li W., Li Y., et al. (2026). Amino acid transporter SLC7A11 functions in ferroptosis regulation and immune microenvironment in osteosarcoma. Int. Immunopharmacol. 168, 115876. 10.1016/j.intimp.2025.115876 [DOI] [PubMed] [Google Scholar]
  20. Jiang X., Stockwell B. R., Conrad M. (2021). Ferroptosis: mechanisms, biology and role in disease. Nat. Rev. Mol. Cell. Biol. 22, 266–282. 10.1038/s41580-020-00324-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Li J., Cao F., Yin H. L., Huang Z. J., Lin Z. T., Mao N., et al. (2020a). Ferroptosis: past, present and future. Cell. Death Dis. 11, 88. 10.1038/s41419-020-2298-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Li T., Jiang D., Wu K. (2020b). p62 promotes bladder cancer cell growth by activating KEAP1/NRF2-dependent antioxidative response. Cancer Sci. 111, 1156–1164. 10.1111/cas.14321 [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Li Y., Zhang H., Merkher Y., Chen L., Liu N., Leonov S., et al. (2022a). Recent advances in therapeutic strategies for triple-negative breast cancer. J. Hematol. Oncol. 15, 121. 10.1186/s13045-022-01341-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Li J. K., Sun H. T., Jiang X. L., Chen Y. F., Zhang Z., Wang Y., et al. (2022b). Polyphyllin II induces protective autophagy and apoptosis via inhibiting PI3K/AKT/mTOR and STAT3 signaling in colorectal cancer cells. Int. J. Mol. Sci. 23, 11890. 10.3390/ijms231911890 [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Li J., He D., Li S., Xiao J., Zhu Z. (2023a). Ferroptosis: the emerging player in remodeling triple-negative breast cancer. Front. Immunol. 14, 1284057. 10.3389/fimmu.2023.1284057 [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Li J., Wu Z., Chen G., Wang X., Zhu X., Zhang Y., et al. (2023b). Formosanin C inhibits non-small-cell lung cancer progression by blocking MCT4/CD147-mediated lactate export. Phytomedicine 109, 154618. 10.1016/j.phymed.2022.154618 [DOI] [PubMed] [Google Scholar]
  27. Lien E. C., Lyssiotis C. A., Juvekar A., Hu H., Asara J. M., Cantley L. C., et al. (2016). Glutathione biosynthesis is a metabolic vulnerability in PI(3)K/Akt-driven breast cancer. Nat. Cell. Biol. 18, 572–578. 10.1038/ncb3341 [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Lin P. L., Tang H. H., Wu S. Y., Shaw N. S., Su C. L. (2020). Saponin formosanin C-induced ferritinophagy and ferroptosis in human hepatocellular carcinoma cells. Antioxidants (Basel) 9 (8), 682. 10.3390/antiox9080682 [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Liu P., Anandhan A., Chen J., Shakya A., Dodson M., Ooi A., et al. (2023). Decreased autophagosome biogenesis, reduced NRF2, and enhanced ferroptotic cell death are underlying molecular mechanisms of non-alcoholic fatty liver disease. Redox Biol. 59, 102570. 10.1016/j.redox.2022.102570 [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Liu F., Xiao J. H., Song Y. J., Zeng C. C. (2026). Ferroptosis and its role in immune modulation in breast cancer. Apoptosis 31, 49. 10.1007/s10495-026-02258-6 [DOI] [PubMed] [Google Scholar]
  31. Luo M., Bao L., Xue Y., Zhu M., Kumar A., Xing C., et al. (2024). ZMYND8 protects breast cancer stem cells against oxidative stress and ferroptosis through activation of NRF2. J. Clin. Investig. 134, e171166. 10.1172/jci171166 [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Mehraj U., Mushtaq U., Mir M. A., Saleem A., Macha M. A., Lone M. N., et al. (2022). Chemokines in triple-negative breast cancer heterogeneity: new challenges for clinical implications. Semin. Cancer Biol. 86, 769–783. 10.1016/j.semcancer.2022.03.008 [DOI] [PubMed] [Google Scholar]
  33. Mou Y., Wang J., Wu J., He D., Zhang C., Duan C., et al. (2019). Ferroptosis, a new form of cell death: opportunities and challenges in cancer. J. Hematol. Oncol. 12, 34. 10.1186/s13045-019-0720-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Qiu Y., Wang X., Sun Y., Jin T., Tang R., Zhou X., et al. (2024). ACSL4-Mediated membrane phospholipid remodeling induces integrin β1 activation to facilitate triple-negative breast cancer metastasis. Cancer Res. 84, 1856–1871. 10.1158/0008-5472.Can-23-2491 [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Ren D., Villeneuve N. F., Jiang T., Wu T., Lau A., Toppin H. A., et al. (2011). Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Proc. Natl. Acad. Sci. U. S. A. 108, 1433–1438. 10.1073/pnas.1014275108 [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Stockwell B. R., Friedmann Angeli J. P., Bayir H., Bush A. I., Conrad M., Dixon S. J., et al. (2017). Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 171, 273–285. 10.1016/j.cell.2017.09.021 [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Sun X., Ou Z., Chen R., Niu X., Chen D., Kang R., et al. (2016). Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. Hepatology 63, 173–184. 10.1002/hep.28251 [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Sung H., Ferlay J., Siegel R. L., Laversanne M., Soerjomataram I., Jemal A., et al. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249. 10.3322/caac.21660 [DOI] [PubMed] [Google Scholar]
  39. Szulc A., Woźniak M. (2025). Targeting ferroptosis as the achilles' heel of breast cancer: mechanisms and therapeutic opportunities from a comprehensive systematic review. Int. J. Mol. Sci. 26, 9902. 10.3390/ijms26209902 [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Tan L. K., Liu J., Ma C. Z., Huang S., He F. H., Long Y., et al. (2025). Iron-dependent cell death: exploring ferroptosis as a unique target in triple-negative breast cancer management. Cancer Manag. Res. 17, 625–637. 10.2147/cmar.S503932 [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Todoric J., Antonucci L., Di Caro G., Li N., Wu X., Lytle N. K., et al. (2017). Stress-activated NRF2-MDM2 Cascade controls neoplastic progression in pancreas. Cancer Cell. 32, 824–839.e828. 10.1016/j.ccell.2017.10.011 [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Tunc R., Ates I., Yılmaz B., Medoro A., Davinelli S., Suzen S., et al. (2025). Modulating Nrf2 to control lipid peroxidation and ferroptosis: implications for cancer management. Front. Oncol. 15, 1701249. 10.3389/fonc.2025.1701249 [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Verma N., Vinik Y., Saroha A., Nair N. U., Ruppin E., Mills G., et al. (2020). Synthetic lethal combination targeting BET uncovered intrinsic susceptibility of TNBC to ferroptosis. Sci. Adv. 6. 10.1126/sciadv.aba8968 [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Wang Z., Li R., Hou N., Zhang J., Wang T., Fan P., et al. (2023a). PRMT5 reduces immunotherapy efficacy in triple-negative breast cancer by methylating KEAP1 and inhibiting ferroptosis. J. Immunother. Cancer 11, e006890. 10.1136/jitc-2023-006890 [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Wang Y., Chen Y. Y., Gao G. B., Zheng Y. H., Yu N. N., Ouyang L., et al. (2023b). Polyphyllin D punctures hypertrophic lysosomes to reverse drug resistance of hepatocellular carcinoma by targeting acid sphingomyelinase. Mol. Ther. 31, 2169–2187. 10.1016/j.ymthe.2023.05.015 [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Wang W., Aguilar M., Datta S., Alley A., Tadesse M., Wang X., et al. (2025). Dual inhibitor of MDM2 and NFAT1 for experimental therapy of breast cancer: in vitro and in vivo anticancer activities and newly discovered effects on cancer metabolic pathways. Front. Pharmacol. 16, 16–20. 10.3389/fphar.2025.1531667 [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Wu R. T., Chiang H. C., Fu W. C., Chien K. Y., Chung Y. M., Horng L. Y. (1990). Formosanin-C, an immunomodulator with antitumor activity. Int. J. Immunopharmacol. 12, 777–786. 10.1016/0192-0561(90)90042-l [DOI] [PubMed] [Google Scholar]
  48. Xu Z., Chen X., Song L., Yuan F., Yan Y. (2022). Matrix remodeling-associated protein 8 as a novel indicator contributing to glioma immune response by regulating ferroptosis. Front. Immunol. 13, 834595. 10.3389/fimmu.2022.834595 [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Yan Y., Liang Q., Xu Z., Huang J., Chen X., Cai Y., et al. (2021). Downregulated ferroptosis-related gene STEAP3 as a novel diagnostic and prognostic target for hepatocellular carcinoma and its roles in immune regulation. Front. Cell. Dev. Biol. 9, 743046. 10.3389/fcell.2021.743046 [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Yang F., Xiao Y., Ding J. H., Jin X., Ma D., Li D. Q., et al. (2023). Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy. Cell. Metab. 35, 84–100.e108. 10.1016/j.cmet.2022.09.021 [DOI] [PubMed] [Google Scholar]
  51. Yang R., Gao W., Wang Z., Jian H., Peng L., Yu X., et al. (2024). Polyphyllin I induced ferroptosis to suppress the progression of hepatocellular carcinoma through activation of the mitochondrial dysfunction via Nrf2/HO-1/GPX4 axis. Phytomedicine 122, 155135. 10.1016/j.phymed.2023.155135 [DOI] [PubMed] [Google Scholar]
  52. Yu S., Wang L., Cao Z., Gong D., Liang Q., Chen H., et al. (2018). Anticancer effect of polyphyllin Ι in colorectal cancer cells through ROS-Dependent autophagy and G2/M arrest mechanisms. Nat. Prod. Res. 32, 1489–1492. 10.1080/14786419.2017.1353512 [DOI] [PubMed] [Google Scholar]
  53. Zefrei F. J., Shormij M., Dastranj L., Alvandi M., Shaghaghi Z., Farzipour S., et al. (2024). Ferroptosis inducers as promising radiosensitizer agents in cancer radiotherapy. Curr. Radiopharm. 17, 14–29. 10.2174/0118744710262369231110065230 [DOI] [PubMed] [Google Scholar]
  54. Zhao B., Wang Z., Han J., Wei G., Yi B., Li Z. (2020). Rhizoma paridis total saponins alleviate H2O2-induced oxidative stress injury by upregulating the Nrf2 pathway. Mol. Med. Rep. 21, 220–228. 10.3892/mmr.2019.10827 [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Zhao Y., Xu C., Liu Y., Zhu Y., Fan L., Gao F., et al. (2026). AR/ERK co-targeting triggers ferroptosis via FOXC2 in triple-negative breast cancer. Sci. China Life Sci. 69, 85–100. 10.1007/s11427-025-3044-4 [DOI] [PubMed] [Google Scholar]
  56. Zhou C., Yu T., Zhu R., Lu J., Ouyang X., Zhang Z., et al. (2023). Timosaponin AIII promotes non-small-cell lung cancer ferroptosis through targeting and facilitating HSP90 mediated GPX4 ubiquitination and degradation. Int. J. Biol. Sci. 19, 1471–1489. 10.7150/ijbs.77979 [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Zhu Y., Zhu X., Tang C., Guan X., Zhang W. (2021). Progress and challenges of immunotherapy in triple-negative breast cancer. Biochim. Biophys. Acta Rev. Cancer 1876, 188593. 10.1016/j.bbcan.2021.188593 [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Articles from Frontiers in Pharmacology are provided here courtesy of Frontiers Media SA

RESOURCES